Here are the 10-K annual reports from Acadia Pharmaceuticals Inc. (ACAD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ACAD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACAD filings page.
Acadia Pharmaceuticals is a biopharmaceutical company focused on neurological and rare diseases, built around two commercial drugs: NUPLAZID for Parkinson’s disease psychosis and DAYBUE for Rett syndrome. Net product sales from these medicines reached $1,071.5 million in 2025, up from $957.8 million in 2024, reflecting strong franchise growth.
The company is investing heavily in its pipeline, led by remlifanserin, now in Phase 2 trials for Alzheimer’s disease psychosis and Lewy Body Dementia psychosis, and ACP-211 in a Phase 2 study for major depressive disorder. It plans a Phase 2 trial of ACP-711 in essential tremor in late 2026 and a Phase 1 study of ACP-271 for tardive dyskinesia and Huntington’s disease in early 2026. ACP-101 for Prader‑Willi syndrome was discontinued after a Phase 3 failure.
Acadia is expanding DAYBUE globally, with approvals in Canada and Israel and an EU marketing application that recently received a negative trend vote, for which it intends to seek re‑examination. As of June 30, 2025, non‑affiliate market value was about $2.3 billion, and 170,494,613 shares were outstanding as of February 18, 2026.